TOP > 外国特許検索 > Therapeutic agent for treating Trypanosoma-associated disease, method for killing Trypanosoma parasites, and use thereof

Therapeutic agent for treating Trypanosoma-associated disease, method for killing Trypanosoma parasites, and use thereof UPDATE

外国特許コード F190009908
整理番号 08193-US
掲載日 2019年8月26日
出願国 アメリカ合衆国
出願番号 201414509262
公報番号 20150099795
公報番号 9803206
出願日 平成26年10月8日(2014.10.8)
公報発行日 平成27年4月9日(2015.4.9)
公報発行日 平成29年10月31日(2017.10.31)
優先権データ
  • 特願2013-211448 (2013.10.8) JP
発明の名称 (英語) Therapeutic agent for treating Trypanosoma-associated disease, method for killing Trypanosoma parasites, and use thereof UPDATE
発明の概要(英語) A therapeutic agent for treating a Trypanosoma-associated disease; a method of preventing infection by Trypanosoma parasites, or killing Trypanosoma parasites; and use thereof, the therapeutic agent and the method each using a mechanism different from a mechanism used in conventional technology. The therapeutic agent of the present invention for treating a Trypanosoma-associated disease includes, as a medicinal component, an antisense oligonucleotide suppressing the expression of an inositol 1,4,5-trisphosphate receptor protein of Trypanosoma parasites.
従来技術、競合技術の概要(英語) BACKGROUND ART
A Trypanosoma-associated disease, or trypanosomiasis, is a general term for diseases that develop due to infection by the parasitic protozoan of the genus Trypanosoma of the phylum kinetoplastea of the superclass Mastigophora. Every year, many humans and animals such as farm animals are reported to have died from Trypanosoma-associated diseases. The damages caused by Trypanosoma parasites are tremendous and serious.
Several therapeutic agents for treating a Trypanosoma-associated disease have been developed so far. However, those therapeutic agents must be used in early treatment, and also have problems such as production of severe side effects and development of resistant trypanosomes. No vaccine for treating a Trypanosoma-associated disease has been developed so far, and no effective therapeutic agent or method has been established as well.
As treatment of a disease, there is known a state-of-the-art treatment which uses an oligonucleotide and works by silencing a gene that responds to the disease. Examples of such a therapeutic method include a treatment which uses RNA interference using dsRNA (Non-patent Literature 1).
However, it has been reported that against Trypanosoma cruzi, which is a pathogen of American trypanosomiasis (Chagas disease), RNA interference cannot be achieved since dsRNA is degraded in both epimastigotes which are parasitic in insect vectors and amastigotes which have a proliferative phase in mammalian cells (Non-patent Literature 2).
特許請求の範囲(英語) [claim1]
1. A therapeutic agent for treating a Trypanosoma-associated disease, comprising, as a medicinal component, a therapeutically effective amount of a synthesized antisense oligonucleotide suppressing the expression of an inositol 1,4,5-trisphosphate receptor protein of Trypanosoma parasites,
wherein the therapeutic agent further comprises at least a preservative.

[claim2]
2. The therapeutic agent as set forth in claim 1, wherein:
the synthesized antisense oligonucleotide is at least two selected from the group consisting of an oligonucleotide including the base sequence of SEQ ID NO: 1, an oligonucleotide including the base sequence of SEQ ID NO: 2, an oligonucleotide including the base sequence of SEQ ID NO: 3, an oligonucleotide including the base sequence of SEQ ID NO: 4, an oligonucleotide including a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 1, an oligonucleotide including a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 2, an oligonucleotide including a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 3, and an oligonucleotide including a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 4.

[claim3]
3. The therapeutic agent as set forth in claim 1, wherein:
the synthesized antisense oligonucleotide is at least two selected from the group consisting of an oligonucleotide consisting of the base sequence of SEQ ID NO: 1, an oligonucleotide consisting of the base sequence of SEQ ID NO: 2, an oligonucleotide consisting of the base sequence of SEQ ID NO: 3, an oligonucleotide consisting of the base sequence of SEQ ID NO: 4, an oligonucleotide consisting of a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 1, an oligonucleotide consisting of a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 2, an oligonucleotide consisting of a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 3, and an oligonucleotide consisting of a base sequence having 90% or more sequence identity with the base sequences of SEQ ID NO: 4.

[claim4]
4. A drug for suppressing the expression of an inositol 1,4,5-trisphosphate receptor protein of Trypanosoma parasites, comprising, as an active component, an effective amount of a synthesized antisense oligonucleotide suppressing the expression of the inositol 1,4,5-trisphosphate receptor protein,
wherein the drug further comprises at least a preservative.
  • 発明者/出願人(英語)
  • Mikoshiba Katsuhiko
  • Nara Takeshi
  • Hashimoto Muneaki
  • RIKEN
国際特許分類(IPC)

PAGE TOP

close
close
close
close
close
close